866-997-4948(US-Canada Toll Free)

Pharyngeal Neoplasm Pipeline Review, H2 2012

Published By :

Global Markets Direct

Published Date : Oct 2012

Category :

Oncology

No. of Pages : 210 Pages


Pharyngeal Neoplasm Pipeline Review, H2 2012

Global Markets Directs, 'Pharyngeal Neoplasm Pipeline Review, H2 2012', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Pharyngeal Neoplasm, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Pharyngeal Neoplasm. Pharyngeal Neoplasm Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • A snapshot of the global therapeutic scenario for Pharyngeal Neoplasm.
  • A review of the Pharyngeal Neoplasm products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Pharyngeal Neoplasm pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for Pharyngeal Neoplasm.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Pharyngeal Neoplasm pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents

Table of Contents 2

List of Tables 12
List of Figures 13
Introduction 14
Global Markets Direct Report Coverage 14
Pharyngeal Neoplasm Overview 15
Therapeutics Development 16
An Overview of Pipeline Products for Pharyngeal Neoplasm 16
Pharyngeal Neoplasm Therapeutics under Development by Companies 18
Pharyngeal Neoplasm Therapeutics under Investigation by Universities/Institutes 19
Late Stage Products 24
Comparative Analysis 24
Mid Clinical Stage Products 25
Comparative Analysis 25
Early Clinical Stage Products 26
Comparative Analysis 26
Discovery and Pre-Clinical Stage Products 27
Comparative Analysis 27
Pharyngeal Neoplasm Therapeutics Products under Development by Companies 28
Pharyngeal Neoplasm Therapeutics Products under Investigation by Universities/Institutes 29
Companies Involved in Pharyngeal Neoplasm Therapeutics Development 35
F. Hoffmann-La Roche Ltd. 35
Sanofi-Aventis 36
YM BioSciences Inc. 37
Cyclacel Pharmaceuticals Inc. 38
Advaxis, Inc. 39
Prima BioMed Limited 40
Jiangsu Hengrui Medicine Co., Ltd. 41
Biotech Pharmaceuticals Co., Ltd. 42
Pharyngeal Neoplasm Therapeutics Assessment 43
Assessment by Monotherapy Products 43
Assessment by Combination Products 44
Assessment by Route of Administration 45
Assessment by Molecule Type 47
Drug Profiles 49
seliciclib - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
ADXS-HPV - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
Cisplatin + Radiation Therapy - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
HPPH - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
Vorinostat + Capecitabine - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
Cetuximab + Cisplatin - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
Cisplatinum + Radiotherapy - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
Xeloda + Oxaliplatin - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
cisplatin - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
Gemcitabine + Cisplatin + Radiation Therapy - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
EBNA-1 - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
Fludarabine + Radiation Therapy - Drug Profile 84
Product Description 84
Mechanism of Action 84
R&D Progress 84
Cisplatin + Fluorouracil + Radiation Therapy - Drug Profile 85
Product Description 85
Mechanism of Action 85
R&D Progress 85
Radiation Therapy + Cetuximab - Drug Profile 86
Product Description 86
Mechanism of Action 86
R&D Progress 86
Docetaxel + Cisplatin + 5-Fluorouracil + Radiation Therapy - Drug Profile 88
Product Description 88
Mechanism of Action 88
R&D Progress 89
Docetaxel + Cisplatin - Drug Profile 90
Product Description 90
Mechanism of Action 90
R&D Progress 90
Docetaxel + Cisplatin + 5-Fluorouracil + Radiation Therapy - Drug Profile 92
Product Description 92
Mechanism of Action 92
R&D Progress 92
Paclitaxel + Cisplatin + Cetuximab + Radiation Therapy - Drug Profile 94
Product Description 94
Mechanism of Action 94
R&D Progress 95
Cisplatin + Fluorouracil + Radiation Therapy - Drug Profile 96
Product Description 96
Mechanism of Action 96
R&D Progress 96
Docetaxel + Cisplatin + Fluorouracil - Drug Profile 98
Product Description 98
Mechanism of Action 98
R&D Progress 99
Cisplatin + Erlotinib + Radiation Therapy - Drug Profile 100
Product Description 100
Mechanism of Action 100
R&D Progress 100
nimotuzumab - Drug Profile 102
Product Description 102
Mechanism of Action 102
R&D Progress 102
Vorinostat + Cisplatin + Radiation Therapy - Drug Profile 104
Product Description 104
Mechanism of Action 104
R&D Progress 104
Sorafenib + Cisplatin + 5-Fluorouracil - Drug Profile 105
Product Description 105
Mechanism of Action 105
R&D Progress 105
Gemcitabine + Carboplatin - Drug Profile 107
Product Description 107
Mechanism of Action 107
R&D Progress 107
bortezomib - Drug Profile 109
Product Description 109
Mechanism of Action 109
R&D Progress 109
Mitomycin C + Epirubicin + Cisplatin + 5-Fluorouracil + Leucovorin - Drug Profile 124
Product Description 124
Mechanism of Action 124
R&D Progress 125
Docetaxel + Radiation Therapy - Drug Profile 126
Product Description 126
Mechanism of Action 126
R&D Progress 126
Cisplatin + Intensity-Modulated Radiation Therapy - Drug Profile 127
Product Description 127
Mechanism of Action 127
R&D Progress 127
Cisplatin + 5FU + Taxotere - Drug Profile 129
Product Description 129
Mechanism of Action 129
R&D Progress 129
Cisplatin + Fluorouracil + Docetaxel + Cetuximab - Drug Profile 131
Product Description 131
Mechanism of Action 131
R&D Progress 132
Cisplatin + Cytochlor + Tetrahydrouridine + Radiation Therapy - Drug Profile 133
Product Description 133
Mechanism of Action 133
R&D Progress 133
Cisplatinum + Fluorouracil + Radiotherapy - Drug Profile 135
Product Description 135
Mechanism of Action 135
R&D Progress 135
Recombinant Epstein-Barr Virus (EBV) Vaccine - Drug Profile 137
Product Description 137
Mechanism of Action 137
R&D Progress 137
Interleukin + NK Cells - Drug Profile 138
Product Description 138
Mechanism of Action 138
R&D Progress 138
Amifostine + Cisplatin + Fluorouracil + Radiation Therapy - Drug Profile 154
Product Description 154
Mechanism of Action 154
R&D Progress 154
Cisplatin + Paclitaxel + Radiation Therapy - Drug Profile 156
Product Description 156
Mechanism of Action 156
R&D Progress 156
Lapatinib Ditosylate + Capecitabine - Drug Profile 157
Product Description 157
Mechanism of Action 157
R&D Progress 157
Taxotere + Cisplatin + 5-FU - Drug Profile 159
Product Description 159
Mechanism of Action 159
R&D Progress 159
Cisplatin + Radiation Therapy - Drug Profile 161
Product Description 161
Mechanism of Action 161
R&D Progress 161
Erbitux + Radiation Therapy - Drug Profile 162
Product Description 162
Mechanism of Action 162
R&D Progress 162
Docetaxel + Cisplatin + Radiation Therapy - Drug Profile 183
Product Description 183
Mechanism of Action 183
R&D Progress 183
Gemcitabine + Valproic acid + Valganciclovir - Drug Profile 185
Product Description 185
Mechanism of Action 185
R&D Progress 185
Famitinib + Cisplatin + Radiation Therapy - Drug Profile 187
Product Description 187
Mechanism of Action 187
R&D Progress 187
Nedaplatin + Radiation Therapy - Drug Profile 189
Product Description 189
Mechanism of Action 189
R&D Progress 189
Celecoxib + Radiation Therapy - Drug Profile 190
Product Description 190
Mechanism of Action 190
R&D Progress 190
Cripto-1 Monoclonal Antibody - Drug Profile 191
Product Description 191
Mechanism of Action 191
R&D Progress 191
Gemcitabine + Cisplatin + Cytokine induced killer cells - Drug Profile 192
Product Description 192
Mechanism of Action 192
R&D Progress 192
Pharyngeal Neoplasm Therapeutics Drug Profile Updates 193
Pharyngeal Neoplasm Therapeutics Discontinued Products 198
Pharyngeal Neoplasm Therapeutics - Dormant Products 200
Pharyngeal Neoplasm Product Development Milestones 204
Featured News & Press Releases 204
Dec 16, 2011: Radiation Therapy Oncology Group Trial Results Show Bevacizumab Reduces Spread Of Nasopharyngeal Cancer 204
May 29, 2009: Cyclacel Reports Initial Phase 2 Seliciclib Data In Patients With Nasopharyngeal Carcinoma At 2009 Asco Annual Meeting 205
Apr 21, 2009: Cyclacel & Dartmouth Researchers Reports Novel Mechanism Of Action For Seliciclib At AACR 205
Mar 05, 2009: Cyclacel Announces Phase 1 Data Elucidating Pharmacodynamics & Mechanism Of Action Of Seliciclib In Nasopharyngeal Cancer 206
Oct 07, 2008: Epstein-Barr Virus Protein Contributes to Cancer 207
Aug 28, 2008: CYCLACEL Announces Recommendations Of Data Review Committee For Seliciclib Phase 2b Non-Small Cell Lung Cancer APPRAISE Trial 207
Jun 28, 2007: Cyclacel Pharmaceuticals Announces Results Of Phase II Seliciclib Combination Studies 208

Appendix 209
Methodology 209
Coverage 209
Secondary Research 209
Primary Research 209
Expert Panel Validation 209
Contact Us 210
Disclaimer 210

List of Table


Number of Products Under Development for Pharyngeal Neoplasm, H2 2012 16
Products under Development for Pharyngeal Neoplasm Comparative Analysis, H2 2012 17
Number of Products under Development by Companies, H2 2012 18
Number of Products under Investigation by Universities/Institutes, H2 2012 20
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..1) 21
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..2) 22
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..3) 23
Comparative Analysis by Late Stage Development, H2 2012 24
Comparative Analysis by Mid Clinical Stage Development, H2 2012 25
Comparative Analysis by Early Clinical Stage Development, H2 2012 26
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 27
Products under Development by Companies, H2 2012 28
Products under Investigation by Universities/Institutes, H2 2012 29
Products under Investigation by Universities/Institutes, H2 2012 (Contd..1) 30
Products under Investigation by Universities/Institutes, H2 2012 (Contd..2) 31
Products under Investigation by Universities/Institutes, H2 2012 (Contd..3) 32
Products under Investigation by Universities/Institutes, H2 2012 (Contd..4) 33
Products under Investigation by Universities/Institutes, H2 2012 (Contd..5) 34
F. Hoffmann-La Roche Ltd., H2 2012 35
Sanofi-Aventis, H2 2012 36
YM BioSciences Inc., H2 2012 37
Cyclacel Pharmaceuticals Inc., H2 2012 38
Advaxis, Inc., H2 2012 39
Prima BioMed Limited, H2 2012 40
Jiangsu Hengrui Medicine Co., Ltd., H2 2012 41
Biotech Pharmaceuticals Co., Ltd., H2 2012 42
Assessment by Monotherapy Products, H2 2012 43
Assessment by Combination Products, H2 2012 44
Assessment by Stage and Route of Administration, H2 2012 46
Assessment by Stage and Molecule Type, H2 2012 48
Pharyngeal Neoplasm Therapeutics Drug Profile Updates 193
Pharyngeal Neoplasm Therapeutics Discontinued Products 198
Pharyngeal Neoplasm Therapeutics Discontinued Products (Contd..1) 199
Pharyngeal Neoplasm Therapeutics Dormant Products 200
Pharyngeal Neoplasm Therapeutics Dormant Products (Contd..1) 201
Pharyngeal Neoplasm Therapeutics Dormant Products (Contd..2) 202
Pharyngeal Neoplasm Therapeutics Dormant Products (Contd..3) 203

List of Chart


Number of Products under Development for Pharyngeal Neoplasm, H2 2012 16
Products under Development for Pharyngeal Neoplasm Comparative Analysis, H2 2012 17
Products under Development by Companies, H2 2012 18
Products under Investigation by Universities/Institutes, H2 2012 19
Late Stage Products, H2 2012 24
Mid Clinical Stage Products, H2 2012 25
Early Clinical Stage Products, H2 2012 26
Discovery and Pre-Clinical Stage Products, H2 2012 27
Assessment by Monotherapy Products, H2 2012 43
Assessment by Combination Products, H2 2012 44
Assessment by Route of Administration, H2 2012 45
Assessment by Stage and Route of Administration, H2 2012 46
Assessment by Molecule Type, H2 2012 47
Assessment by Stage and Molecule Type, H2 2012 48

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *